Drug delivery of sensitive biopharmaceuticals with prefilled syringes

Drug Delivery Technology

Volumn 9, Issue 5, 2009, Pages 22-27

  Fries, Arno ^a  

^a Gerresheimer Buende GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SILICON; TUNGSTEN;

ARTICLE; BIOTECHNOLOGICAL PRODUCTION; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; EQUIPMENT DESIGN; MATERIAL COATING; MOLECULAR STABILITY; PH; PHARMACEUTICAL ENGINEERING; PHYSICAL PHASE; PROCESS OPTIMIZATION; PRODUCT DEVELOPMENT; SOCIAL MARKETING; SYRINGE;

EID: 69949178862     PISSN: 15372898     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (40)

1. Allain L, Wang Q. Impact of package leachables on the stability of pharmaceutical products. Am Pharm Rev. 2007;10(4):38-44.
2. Nicholas K. Extractables and leachables determination: a systemic approach to select and quantify a container closure system for a pharmaceutical product. Am Pharm Rev. 2006;9(3):21-27.
3. Marcovic I. CDER case studies of leaching problems in biotech products. Int Pharm Qual. 2008;2(2):25-26.
4. DeGrazio FL. Parenteral Packaging concerns for biotech drug products. Drug Delivery Technology. 2006;6(5):44-49.
5. Jenke D. Suitability-for-use considerations for prefilled syringes: drug delivery. Pharm Technol. 2008:s30-s33.
6. Markovic I. Evaluation of safety and quality impact of extractable and leachable substances in therapeutic biologic protein products: a risk-based perspective. Expert Opin Drug Saf. 2007;6(5):487-491.
7. Jones LS, Kaufmann A, Middaugh CR. Silicone oil induced aggregation of proteins. J Pharm Sci. 2005;94(4):918-927.
8. Rosenberg AS. Effects of protein aggregates, an immunologic perspective. AAPS Journal. 2006;8(3):E501-E507.
9. Das T, Nema S. Protein particulate issues in biologies development. Am Pharm Rev. 2008;11(4):52-57.
10. Scott C. Formulation development: making the medicine. BioProcess Internat. 2006;4(3):42-57.
11. Romacker M, Schoenknecht T, Forster R. The rise of prefilled syringes from niche product to primary container of choice: a short history. ONdrugDelivery. 2008;4:4-5.
12. Romacker M. The role of the prefilled syringe in a changing pharmaceutical world. Serip World Pharm News. 2004;10(supplement):10-12.
13. Harrison B, Rios M. Big shot, developments in prefilled syringes. Pharm Technol. 2007;31(3):50-60.
14. Overcashier DE, Chan EK, Hsu CC. Technical considerations in the development of prefilled syringes for protein products. Am Pharm Rev. 2006;9(7):77-83.
15. Eakins MN. The design and construction of prefilled syringes. Am Pharm Rev. 2007;10(6):47-51.
16. Fries A. Neue Erkenntnisse über den Markt von Fertigspritzen. Pharm Ind. 2008;70(8)929-933.
17. Fries A, Lingenberg B. New market insight into prefilled syringes and closure systems: primary data from patients, nurses, physicians, and industry experts. ONdrugDelivery. 2008;4:39-41.
18. Greystone Associates. Prefilled syringes: drugs, devices and delivery strategies. Market Study; 2006.
19. Frost & Sullivan. US Pharmaceutical Packaging Markets. Market Study; 2005.
20. MEFOS Gesellschaft für Meinungsforschung und Beratung im Gesundheitswesen. Market Study; 2007.
21. Vogel W. Glass Chemistry. Springer Verlag, Berlin and Heidelberg, 2nd Edition; 1994.
22. Wlecke M. Technical Study. Unpublished Results; 2008.
23. ISO 4802-2. Glassware: Hydrolytic Resistance of the Unterior Surfaces of Glass Containers, Part 2: Determination by Flame Spectrometry and Classification. 1st Edition; 1988.
24. European Pharmacopoeia. Glass Containers for Pharmaceutical Use. 30201, 303-308; 2005.
25. Fries A, Schoenknecht T. Controlling the alkali release in glass based prefillable syringes. Poster presented at the AAPS Annual Meeting and Exposition. San Diego, CA, November 13, 2007.
26. Osterberg RE. Potential toxicity of extractables and leachables in drug products. Am Pharm Rev. 2005;8(2):64-67.
27. Markovic I. Challenges associated with extractable and/or leachable substances in therapeutic biologic protein products. Am Pharm Rev. 2006;9(6):20-27.
28. Rosenberg AS, Worobec AS. A risk-based approach to immunogenicity concerns of therapeutic protein products, part 2: considering host-specific and product-specific factors impacting immunogenicity. BioPharm Int. 2004;17(12):34-40.
29. Faulkner E. Container closure interactions with biopharmaceutical parental products. Paper presented at the ICB Annual Formulation Strategies for Protein Therapeutics Conference. San Francisco, CA. November 6-8, 2006.
30. Lee H. Tungsten leaching from prefilled syringes and impact on protein aggregation. Poster presented at the PDA Extractables/Leachables Forum. Bethesada, MD. November 6-8, 2007.
31. Lassner E, Schubert WD. Tungsten: properties, chemistry, technology of the element, alloys and chemical compounds. 1st ed. Kluver Academic/ Plenum Publishers: New York, NY;1999.
32. Hecker J. Prefilled syringe, autoinjector quality assurance explored at FDA/industry forum. Pharma Biotechnol Quality Control. (The Gold Sheet) 2007;41(1):1-4.
33. Swift R. Tungsten, prefilled syringes and protein aggregation. Paper presented at the PDA Universe of Prefilled Syringes and Injection Devices Conference. Bethesada, MD. October 23, 2006.
34. International Tungsten Industry Association. Tungsten Uses, Chemical Applications, Catalysts. Website visited January 2009: www.itia.org.uk.
35. Tomanek W. Silicones: synthesis, properties and applications. Polymeric Mater Encyc. 1996;10:7706-7711.
36. Curtis J. Medical Applications of Silicones, Biomaterials Sciences. 2nd ed. Elsevier Pub: New York, NY;2004.
37. Mundry T, Schurreit T, Surmann P. The fate silicone oil during heat-curing glass siliconization: changes in molecular parameters analyzed by size exclusion and high temperature gas chromatography. PDA J Pharm Sci Technol. 2000;54(5):383-397.
38. Mundry T. Einbrennsilikonisierung bei Pharmazeutischen Glaspackmitte. In: Analytische Studien eines Produktionsprozesses. PhD Thesis, Humboldt University, Berlin; 1999.
39. Lankers M. Optimization Study of Baked-in Siliconization in Cartridges. Paper presented at the PDA Interest Group Meeting. Prefilled Syringes, Berlin, Germany. December 2, 2008.
40. Fries A, Khandke L, Malone R. Customization of Prefilled Syringe Systems for Biopharmaceutical Development: case Study. paper presented at the PDA Universe of Prefilled Syringes and Injection Devices Coference, Berlin, Germany. November 28, 2007